Accueil › Cancer du poumon non à petites cellules › Maine

Essais cliniques pour Cancer du poumon non à petites cellules dans Maine

16 études pour Cancer du poumon non à petites cellules recherchent des participants dans Maine.

Villes dans Maine

Texte officiel de l'étude (anglais)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
et 5 autres

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT04267848

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Maine Medical Center- Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT06498635

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

New England Cancer Specialists ( Site 0139), Westbrook

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 28 sept. 2026 · NCT07190248

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Maine Medical Center, Portland
MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06758401

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

New England Cancer Specialists ( Site 0095), Westbrook

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06312137

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

New England Cancer Specialists ( Site 0143), Westbrook

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

New England Cancer Specialists, Westbrook

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT06890598

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Scarborough

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 18 sept. 2026 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, South Portland

Recrutement en coursPhase 3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 4 sept. 2026 · NCT07291037

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

MaineHealth Coastal Cancer Treatment Center, Bath
MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
MaineHealth Maine Medical Center - Portland, Portland
et 3 autres

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 sept. 2026 · NCT07293247

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 3 juin 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Recrutement en coursPhase 2

Âges de 18 ans et plus · Tous sexes · Mis à jour le 6 mai 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
et 5 autres

Recrutement en coursPhase 2/3

Âges de 18 ans et plus · Tous sexes · Mis à jour le 5 mai 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

Recrutement en coursPhase 2

18 Minutes · Tous sexes · Mis à jour le 5 mai 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
MaineHealth Maine Medical Center - Biddeford, Biddeford
et 7 autres

Recrutement en coursÉtude observationnelle

Âges de 18 ans et plus · Tous sexes · Mis à jour le 17 mars 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Scarborough

Recrutement en coursÉtude observationnelle

Tous âges · Tous sexes · Mis à jour le 28 oct. 2025 · NCT03452774

Source : ClinicalTrials.gov, données récupérées le 1 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.